EVO:NASDAQEvotec SE Analysis

Evotec SE (EVO) is trading at $2.61, well below its DCF-derived fair value of $3.85, suggesting a near‑double upside potential. The stock is currently under pressure, with the 20‑day SMA ($2.85) and 50‑day SMA ($2.95) both sitting above the market price, and the MACD histogram remains negative, confirming a bearish momentum. RSI at 39 hints at a modest oversold condition, yet the 30‑day volatility of 55% and a beta of 1.62 indicate a highly volatile, market‑sensitive profile. Fundamentally, the company reports negative earnings (PE –13.7), slim gross margins (≈11%), and a sizable max drawdown of 47%, underscoring earnings weakness. However, the recent appointment of a global AI head and the successful €116 million convertible bond issuance provide fresh capital and strategic direction, which could catalyze a turnaround.
Given the steep discount to intrinsic value, elevated risk metrics, and the blend of short‑term technical weakness with long‑term structural upside, investors should weigh a cautious stance now, but keep an eye on execution of the AI and pipeline initiatives as potential catalysts for a longer‑term rebound.